Suggested remit: To appraise the clinical and cost effectiveness of rimegepant within its marketing authorisation for treating or preventing migraine.
 
Status Proposed
Process STA 2018
ID number 1539

Provisional Schedule

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators 15 April 2021 - 14 May 2021

Project Team

Project lead Emily Richards

Email enquiries


For further information on how we develop guidance, please see our page about NICE technology appraisal guidance